Related Experiment Video
Updated: Jul 10, 2026
21:55
Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling
Published on: April 2, 2012
Engineering of a stable retroviral gene delivery vector by directed evolution
Halong N Vu1, Joshua D Ramsey, Daniel W Pack
1Department of Chemical and Biomolecular Engineering, University of Illinois, Urbana, Illinois 61801, USA.
Summary
Researchers engineered a more stable murine leukemia virus (MLV) for gene therapy. Mutations in the viral protease significantly increased MLV half-life, improving production and transduction efficiency.
Area of Science:
- Gene Therapy
- Virology
- Molecular Biology
Background:
- Gene therapy relies on efficient and safe delivery vectors.
- Viral vectors, like murine leukemia virus (MLV), offer high efficiency but suffer from instability.
- MLV's short half-life (5-8 hours at 37°C) limits its practical application.
Purpose of the Study:
- To enhance the stability of MLV for improved gene therapy applications.
- To identify mutations that increase MLV infectivity half-life at physiological temperatures.
Main Methods:
- Random mutagenesis of the MLV genome followed by selection for infectivity after prolonged incubation.
- Saturation mutagenesis of the viral protease (PR) at residue 119.
- Generation of double mutants combining PR mutations with alterations in the substrate-binding pocket.
Main Results:
- Isolated MLV variants with doubled half-life after seven rounds of selection.
- Identified a single mutation, G119E in the viral protease, as key to enhanced stability.
- Achieved MLV variants with half-lives up to approximately 40 hours at 37°C.
- Observed two- to fourfold higher viral titers and increased stability with various envelope proteins.
Conclusions:
- Engineered MLV variants exhibit significantly enhanced stability and infectivity.
- These stable MLV variants facilitate easier virus production and higher transduction efficiency.
- The developed MLV platform holds promise for advancing human gene therapy.
